Work

Cytokine Release Syndrome after Haploidentical Stem Cell Transplantation

Year: 2016

Type: article

Abstract: For many patients with hematologic malignancies, hematopoietic stem cell transplantation (HSCT) is the only option for cure. Unfortunately, traditional donor options have been limited for a significant percentage of the population, especially for those other than non-Hispanic whites. Haploidentical transplant (haplo-HSCT) has transformed the field because >95% of patients have an available donor [1]. Although early trials using haplo-HSCT had many difficulties, including high rates of graft-versus-host disease and graft failure, advances in both in vivo and ex vivo product manipulation have demonstrated adults with hematologic malignancies may have similar outcomes with haplo-HSCT as with HLA-matched HSCT [2].

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2016.08.010

Authors: David T. Teachey, Stephan A. Grupp

Institutions: Children's Hospital of Philadelphia, University of Pennsylvania

Language: English

Topic: Hematopoietic Stem Cell Transplantation

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,650